|
Martin-Sanchez F, Compan V, Penin-Franch A, Tapia-Abellan A, Gomez AI, Banos-Gregori MC, Schmidt FI, Pelegrin P. ASC oligomer favors caspase-1CARD domain recruitment after intracellular potassium efflux. J Cell Biol. 2023 Aug 7;222(8):e202003053. doi: 10.1083/jcb.202003053. Epub 2023 Jul 4. PubMed PMID: 37402211; PubMed Central PMCID: PMC10318405.
AÑO: 2023; IF: 7.4
|
37402211
|
Angosto-Bazarra D, Guijarro A, Pelegrin P. Evolution of the gasdermin family and pyroptosis. Dev Comp Immunol. 2023 Dec;149:105060. doi: 10.1016/j.dci.2023.105060. Epub 2023 Sep 19. PubMed PMID: 37734430.
AÑO: 2023; IF: 2.7
|
|
Lozano-Rodriguez R, Avendano-Ortiz J, Montalban-Hernandez K, Ruiz-Rodriguez JC, Ferrer R, Martin-Quiros A, Maroun-Eid C, Gonzalez-Lopez JJ, Fabrega A, Terron-Arcos V, Gutierrez-Fernandez M, Alonso-Lopez E, Cubillos-Zapata C, Fernandez-Velasco M, Perez de Diego R, Pelegrin P, Garcia-Palenciano C, Cueto FJ, Del Fresno C, Lopez-Collazo E. The prognostic impact of SIGLEC5-induced impairment of CD8+ T cell activation in sepsis. EBioMedicine. 2023 Nov;97:104841. doi: 10.1016/j.ebiom.2023.104841. Epub 2023 Oct 25. PubMed PMID: 37890368; PubMed Central PMCID: PMC10630607.
AÑO: 2023; IF: 9.7
|
|
Weber ANR, Tapia-Abellan A, Liu X, Arostegui JI, Pelegrin P, Welzel T, Kuemmerle-Deschner JB. Comment on: Effective ex vivo inhibition of cryopyrin-associated periodic syndrome (CAPS)-associated mutant NLRP3 inflammasome by MCC950/CRID3: Reply. Rheumatology (Oxford). 2023 May 2;62(5):e168-e169. doi: 10.1093/rheumatology/keac718. No abstract available. PubMed PMID: 36562561.
AÑO: 2023; IF: 4.7
|
|
Hurtado-Navarro L, Cuenca-Zamora EJ, Zamora L, Bellosillo B, Such E, Soler-Espejo E, Martinez-Banaclocha H, Hernandez-Rivas JM, Marco-Ayala J, Martinez-Alarcon L, Linares-Latorre L, Garcia-Avila S, Amat-Martinez P, Gonzalez T, Arnan M, Pomares-Marin H, Carreno-Tarragona G, Chen-Liang TH, Herranz MT, Garcia-Palenciano C, Morales ML, Jerez A, Lozano ML, Teruel-Montoya R, Pelegrin P, Ferrer-Marin F. NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy. Cell Rep Med. 2023 Dec 19;4(12):101329. doi: 10.1016/j.xcrm.2023.101329. PubMed PMID: 38118408; PubMed Central PMCID: PMC10772462.
AÑO: 2023; IF: 11.7
|